A Long Term Study of Safety for Long Acting Injectable Risperidone in Patients With Schizophrenia or Schizoaffective Disorder.
Phase 3
Completed
- Conditions
- SchizophreniaSchizoaffective Disorder
- First Posted Date
- 2007-11-14
- Last Posted Date
- 2011-05-17
- Lead Sponsor
- Janssen, LP
- Target Recruit Count
- 811
- Registration Number
- NCT00558298
A Long-term Safety Study for Long-acting Injectable Risperidone in Schizophrenia or Schizoaffective Disorder Patients.
Phase 3
Completed
- Conditions
- SchizophreniaSchizoaffective Disorder
- First Posted Date
- 2007-07-02
- Last Posted Date
- 2011-05-17
- Lead Sponsor
- Janssen, LP
- Target Recruit Count
- 314
- Registration Number
- NCT00495118
A Study Comparing Three Strategies to Switch Patients With Schizophrenia or Schizoaffective Disorder to Risperidone After Unsuccessful Treatment With Olanzapine.
Phase 4
Completed
- Conditions
- Schizoaffective DisorderSchizophrenia
- First Posted Date
- 2006-09-19
- Last Posted Date
- 2010-04-27
- Lead Sponsor
- Janssen, LP
- Target Recruit Count
- 120
- Registration Number
- NCT00378183
A 2-year Study of Patients With Schizophrenia Who Are Treated With Long-acting Injectable Risperidone.
Phase 4
Completed
- Conditions
- Schizophrenia
- First Posted Date
- 2005-12-05
- Last Posted Date
- 2011-05-17
- Lead Sponsor
- Janssen, LP
- Target Recruit Count
- 650
- Registration Number
- NCT00261430
A Study of the Effectiveness and Safety of Risperidone Versus Placebo in the Treatment of Behavioral Disturbances in Patients With Dementia
Phase 3
Completed
- Conditions
- Dementia, VascularDementiaAlzheimer Disease
- First Posted Date
- 2005-11-15
- Last Posted Date
- 2010-12-03
- Lead Sponsor
- Janssen, LP
- Target Recruit Count
- 626
- Registration Number
- NCT00253123
A Study of the Effectiveness and Safety of Long-acting Injectable Risperidone Versus Placebo in the Treatment of Patients With Schizophrenia
Phase 3
Completed
- Conditions
- SchizophreniaPsychotic Disorders
- First Posted Date
- 2005-11-15
- Last Posted Date
- 2010-12-03
- Lead Sponsor
- Janssen, LP
- Target Recruit Count
- 458
- Registration Number
- NCT00253136
A Comparison of Risperidone With Haloperidol in Patients With Schizophrenia and Schizoaffective Disorder
Phase 4
Completed
- Conditions
- SchizophreniaSchizoaffective Disorder
- Interventions
- First Posted Date
- 2005-11-15
- Last Posted Date
- 2012-08-06
- Lead Sponsor
- Janssen, LP
- Target Recruit Count
- 396
- Registration Number
- NCT00253110
A Study of the Effectiveness and Safety of Risperidone Compared With Haloperidol in Patients With Chronic Schizophrenia
Phase 3
Completed
- Conditions
- SchizophreniaPsychotic Disorder
- First Posted Date
- 2005-11-07
- Last Posted Date
- 2011-02-11
- Lead Sponsor
- Janssen, LP
- Target Recruit Count
- 1579
- Registration Number
- NCT00249119
A Study of the Effectiveness and Safety of Risperidone Compared With Haloperidol and Placebo in Patients With Chronic Schizophrenia
Phase 3
Completed
- Conditions
- SchizophreniaPsychotic Disorders
- First Posted Date
- 2005-11-07
- Last Posted Date
- 2011-02-11
- Lead Sponsor
- Janssen, LP
- Target Recruit Count
- 523
- Registration Number
- NCT00249132
Observational Study in Patients With Schizophrenia Treated With Long-Acting Risperidone Injection (RISPERDAL CONSTA)
- First Posted Date
- 2005-10-30
- Last Posted Date
- 2014-04-04
- Lead Sponsor
- Janssen, LP
- Target Recruit Count
- 532
- Registration Number
- NCT00246194
© Copyright 2025. All Rights Reserved by MedPath